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Therapeutic decisions for muscle-invasive bladder cancer (MIBC) are largely based on histopathologic
characteristics. In this issue of Cancer Cell, Choi and colleagues report three molecular subtypes of MIBC
with the potential to guide prognosis, patient stratification, and treatment.Despite increased molecular understand-
ing, there has not been a significant
advance in the treatment of muscle-
invasive bladder cancer (MIBC) in recent
years. These tumors frequently become
metastatic, which is associated with very
poor outcome (median survival: approxi-
mately 1 year). The standard of care for
patients with localized MIBC is radical
cystectomy preceded by cisplatin-based
chemotherapy (neoadjuvant chemo-
therapy; NAC), which aims to abolish
undetected metastases (Sternberg et al.,
2013). However, responses to NAC are
recorded in only 40%–60% of cases,
and metastatic disease is frequently de-
tected at the time of surgery. Cisplatin-
containing combination chemotherapy is
also the mainstay of treatment in the
metastatic setting, where both de novo
and acquired resistance present major
problems.
What is needed to improve this dismal
situation? Two issues currently under
investigation may have an impact. First,
predicting the response to chemotherapy
may allow selection for NAC responders,
avoiding unnecessary toxicity in patients
unlikely to respond. Expression signa-
tures associated with sensitivity have
been derived from tumors (Takata et al.,
2005) and tumor cell lines with known
response (Lee et al., 2007), and validation
in relevant clinical trials is eagerly awaited.
Second, identification of therapeutic tar-
gets and development of personalized
treatment strategies is urgently needed.
Although several druggable targets are
present in MIBC, e.g., HER2, EGFR,
FGFR1, and FGFR3, adequate biological
understanding has been lacking, and
few trials with targeted agents have
been initiated.The significant heterogeneity in MIBC
clinical behavior suggests more than one
disease entity. This is already supported
by genome-wide expression and DNA-
based analyses, which report distinct
molecular subtypes. Encouragingly, the
signatures of some of these subtypes
show prognostic value (Sjo¨dahl et al.,
2012). However, this information has yet
to have an impact on clinical manage-
ment, and predictive information has not
been derived from such data.
In this issue of Cancer Cell, Choi et al.
(2014) used whole-genome gene expres-
sion profiling to identify molecular sub-
types of MIBC and provided evidence
for their biological basis and clinical signif-
icance. Their findings have exciting impli-
cations for the clinical management of
MIBC, because they include not only
prognostic information, but also sug-
gestions for subtype-directed targeted
therapy and potential to predict response
to cisplatin-based chemotherapy.
Choi et al. (2014) initially profiled 73
fresh-frozen MIBCs and, using un-
supervised hierarchical cluster analysis,
revealed three major clusters, which they
term basal, luminal and ‘‘p53-like’’. Basal
and luminal designations reflect enrich-
ment for markers previously reported in
basal and luminal-type breast cancers,
respectively (Sørlie, 2004). Basal MIBCs
characteristically expressed CD44,
KRT5, KRT6, KRT14, and CDH3 and
lacked KRT20 expression. Such differen-
tial expression of cytokeratins 5 and 20
is related to urothelial differentiation
states, the least differentiated of which
characterizes cells in the basal layer of
the normal urothelium (KRT14+KRT5+
KRT20) (Volkmer et al., 2012) and
bladder cancer cells with stem cell-likeCancer Cell 25,features (Chan et al., 2009). The basal
subtype also expressed ‘‘mesenchymal’’
markers (TWIST1/2, SNAI2, ZEB2, and
VIM), low miR-200, which is implicated
in mesenchymal marker regulation,
and elevated levels of EGFR and its
ligands. This subtype was enriched for
tumors with sarcomatoid and squamous
features, exhibited more aggressive
disease at presentation, and had shorter
disease-specific and overall survival.
The luminal subtype expressed luminal
breast cancer biomarkers (CD24,
FOXA1, GATA3, ERBB2, ERBB3, XBP1,
and KRT20), ‘‘epithelial’’ biomarkers,
E-cadherin and the miR-200 family and
showed both expression and mutation of
FGFR3. The ‘‘p53-like’’ subtype also
expressed luminal biomarkers but was
distinguished by an activated wild-type
p53 gene signature.
Choi et al. (2014) then developed a
classifier based on genes differentially
expressed between subtypes. Using
this, they were able to identify the same
three subtypes in a local validation cohort
consisting of 57 formalin-fixed paraffin-
embedded (FFPE) MIBC samples and in
a publically available gene expression
data set. As in the initial analysis, these
validation cohorts revealed an associa-
tion between basal subtype and poor sur-
vival. A molecular taxonomy for bladder
cancer described by Sjo¨dahl et al. (2012)
included a subset of squamous cell carci-
noma-like (SCCL) MIBCs that expressed
basal keratins and showed poor prog-
nosis. Recently, these authors have sug-
gested that the term ‘‘basal’’ is more
appropriate for this group (Sjo¨dahl et al.,
2013). Choi et al. (2014) applied their
classifier to this data set and confirmed
that the SCCL group corresponded toFebruary 10, 2014 ª2014 Elsevier Inc. 135
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Previewstheir basal subtype. This analysis also
revealed that the luminal and ‘‘p53-like’’
subtypes shared features with the ‘‘uro-
basal A’’ and ‘‘infiltrated’’ subtypes of Sjo¨-
dahl et al. (2012), respectively. To investi-
gate the association of squamous
features with the basal subtype, Choi
et al. (2014) interrogated data from a pre-
vious study that reported a ‘‘squamous
cluster’’ with KRT5 and KRT14 expression
and found a subset of tumors enriched
with squamous features that expressed
the basal signature. They also examined
expression of cytokeratins that were
characteristic of basal (CK5/6) or luminal
(CK20) tumors in a tissue microarray
derived from 332 MIBCs and found an
inverse correlation of these markers and
association of high CK5/6 with squamous
features.
To investigate the biology of the sub-
types, a bioinformatics approach was
used to seek upstream regulators of
basal and luminal gene expression.
This implicated transcription factors
reportedly active in the basal/stem cell
compartment of the normal urothelium
(Stat-3, NFkB, Hif1, and p63) (Ho et al.,
2012) as potential regulators in basal
MIBCs. Activation of PPARg and estro-
gen receptor pathways was identified in
luminal MIBCs. p63 and PPARg were
then examined in tumor-derived cell
lines. p63 knockdown yielded decreased
basal marker expression and increased
PPAR pathway activation, whereas treat-
ment with a PPARg-selective agonist
activated PPAR and other luminal path-
ways and decreased basal transcription
factor expression, clearly demonstrating
the role of these opposing pathways in
control of these two major phenotypes.
Delineation of these regulators holds
promise for improved therapeutic options
through the use of pathway-specific
targeted agents.136 Cancer Cell 25, February 10, 2014 ª2014Finally, Choi et al. (2014) noted that all
of the NAC-treated ‘‘p53-like’’ MIBCs in
their discovery set (n = 7) showed resis-
tance. Strikingly, this pattern was
confirmed in an expanded local NAC
cohort and 23 archival tumors from a
phase III chemotherapy trial. The ‘‘p53-
like’’ signature was also identified in cell
lines, where it was associated with resis-
tance to cisplatin-induced apoptosis. It
should be noted, however, that, although
the ‘‘p53-like’’ gene expression signature
is characteristic of an activated wild-type
p53 gene signature, it was not related to
TP53 mutation status, an observation
that is reflected in the long-debated
prognostic and predictive value of
mutant p53 in bladder cancer. To con-
firm the link between ‘‘p53-like’’ and
chemoresistance, the authors compared
gene expression profiles from a cohort of
matched pre- and posttreatment sam-
ples from a prospective phase II clinical
trial of NAC. The lowest response rate
was observed in tumors initially classi-
fied as ‘‘p53-like’’. A particularly pleas-
ing feature of this study is that FFPE
samples were successfully used for vali-
dation studies, providing promise for
routine clinical application. Intriguingly,
enrichment of a p53-like signature in
posttreatment tissues from patients
whose pretreatment tissue did not ex-
press this signature was observed.
Whether this reflects global expression
changes or selection of resistant sub-
clones remains to be demonstrated.
Because not all nonresponding tumors
could be identified by this profile,
including those exhibiting basal and
luminal signatures, it is clear that other
biomarkers of resistance remain to be
elucidated, as does the possible con-
tribution of intratumor heterogeneity.
Nevertheless, these findings represent
an important step toward the goal ofElsevier Inc.more rational selection of patients for
chemotherapy.
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